Top

Published in:

Open Access 01-09-2009 | Review

The ubiquitin proteasome system in neuropathology

Author: Norman L. Lehman

Published in: Acta Neuropathologica | Issue 3/2009

Abstract

The ubiquitin proteasome system (UPS) orchestrates the turnover of innumerable cellular proteins. In the process of ubiquitination the small protein ubiquitin is attached to a target protein by a peptide bond. The ubiquitinated target protein is subsequently shuttled to a protease complex known as the 26S proteasome and subjected to degradative proteolysis. The UPS facilitates the turnover of proteins in several settings. It targets oxidized, mutant or misfolded proteins for general proteolytic destruction, and allows for the tightly controlled and specific destruction of proteins involved in development and differentiation, cell cycle progression, circadian rhythms, apoptosis, and other biological processes. In neuropathology, alteration of the UPS, or mutations in UPS target proteins may result in signaling abnormalities leading to the initiation or progression of tumors such as astrocytomas, hemangioblastomas, craniopharyngiomas, pituitary adenomas, and medulloblastomas. Dysregulation of the UPS may also contribute to tumor progression by perturbation of DNA replication and mitotic control mechanisms, leading to genomic instability. In neurodegenerative diseases caused by the expression of mutant proteins, the cellular accumulation of these proteins may overload the UPS, indirectly contributing to the disease process, e.g., sporadic Parkinsonism and prion diseases. In other cases, mutation of UPS components may directly cause pathological accumulation of proteins, e.g., autosomal recessive Parkinsonism and spinocerebellar ataxias. Defects or dysfunction of the UPS may also underlie cognitive disorders such as Angelman syndrome, Rett syndrome and autism, and muscle and nerve diseases, e.g., inclusion body myopathy and giant axon neuropathy. This paper describes the basic biochemical mechanisms comprising the UPS and reviews both its theoretical and proven involvement in neuropathological diseases. The potential for the UPS as a target of pharmacological therapy is also discussed.

Allen E, Ding J, Wang W et al (2005) Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival. Nature 438:224–228PubMedCrossRef

Ardley HC, Scott GB, Rose SA, Tan NG, Robinson PA (2004) UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson’s disease. J Neurochem 90:379–391PubMedCrossRef

Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431:805–810PubMedCrossRef

Bennett EJ, Shaler TA, Woodman B et al (2007) Global changes to the ubiquitin system in Huntington’s disease. Nature 448:704–708PubMedCrossRef

Berke SJ, Chai Y, Marrs GL, Wen H, Paulson HL (2005) Defining the role of ubiquitin-interacting motifs in the polyglutamine disease protein, ataxin-3. J Biol Chem 280:32026–32034PubMedCrossRef

Boland B, Kumar A, Lee S et al (2008) Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer’s disease. J Neurosci 28:6926–6937PubMedCrossRef

Braun CJ, Zhang X, Savelyeva I et al (2008) p53-Responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 68:10094–10104PubMedCrossRef

Buchberger A (2002) From UBA to UBX: new words in the ubiquitin vocabulary. Trends Cell Biol 12:216–221PubMedCrossRef

Buslei R, Nolde M, Hofmann B et al (2005) Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol 109:589–597PubMedCrossRef

10.

Chen C, Seth AK, Aplin AE (2006) Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancer. Mol Cancer Res 4:695–707PubMedCrossRef

11.

Chen Y, Liu W, McPhie DL, Hassinger L, Neve RL (2003) APP-BP1 mediates APP-induced apoptosis and DNA synthesis and is increased in Alzheimer’s disease brain. J Cell Biol 163:27–33PubMedCrossRef

12.

Chen Y, McPhie DL, Hirschberg J, Neve RL (2000) The amyloid precursor protein-binding protein APP-BP1 drives the cell cycle through the S-M checkpoint and causes apoptosis in neurons. J Biol Chem 275:8929–8935PubMedCrossRef

13.

Chenn A, Walsh CA (2002) Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science 297:365–369PubMedCrossRef

14.

Chow N, Korenberg JR, Chen XN, Neve RL (1996) APP-BP1, a novel protein that binds to the carboxyl-terminal region of the amyloid precursor protein. J Biol Chem 271:11339–11346PubMedCrossRef

15.

Chu CT, Caruso JL, Cummings TJ, Ervin J, Rosenberg C, Hulette CM (2000) Ubiquitin immunochemistry as a diagnostic aid for community pathologists evaluating patients who have dementia. Mod Pathol 13:420–426PubMedCrossRef

16.

Cleveland DW, Yamanaka K, Bomont P (2009) Gigaxonin controls vimentin organization through a tubulin chaperone-independent pathway. Hum Mol Genet 18:1384–1394PubMedCrossRef

17.

Cockman ME, Masson N, Mole DR et al (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel–Lindau tumor suppressor protein. J Biol Chem 275:25733–25741PubMedCrossRef

18.

Cook JC, Chock PB (1992) Isoforms of mammalian ubiquitin-activating enzyme. J Biol Chem 267:24315–24321PubMed

19.

Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6:184–192PubMedCrossRef

20.

Cuesta A, Zambrano A, Royo M, Pascual A (2009) The tumour suppressor p53 regulates the expression of amyloid precursor protein (APP). Biochem J 418:643–650PubMedCrossRef

21.

Dayal S, Sparks A, Jacob J, Allende-Vega N, Lane DP, Saville MK (2009) Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J Biol Chem 284:5030–5041PubMedCrossRef

22.

Dil Kuazi A, Kito K, Abe Y, Shin RW, Kamitani T, Ueda N (2003) NEDD8 protein is involved in ubiquitinated inclusion bodies. J Pathol 199:259–266PubMedCrossRef

23.

Dong J, Gailani MR, Pomeroy SL, Reardon D, Bale AE (2000) Identification of PATCHED mutations in medulloblastomas by direct sequencing. Hum Mutat 16:89–90PubMedCrossRef

24.

Duka T, Duka V, Joyce JN, Sidhu A (2009) α-Synuclein contributes to GSK-3β-catalyzed Tau phosphorylation in Parkinson’s disease models. FASEB J (in press)

25.

Dusonchet J, Bensadoun JC, Schneider BL, Aebischer P (2009) Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson’s disease. Neurobiol Dis 35(1):32–41PubMedCrossRef

26.

Eide EJ, Woolf MF, Kang H et al (2005) Control of mammalian circadian rhythm by CKIepsilon-regulated proteasome-mediated PER2 degradation. Mol Cell Biol 25:2795–2807PubMedCrossRef

27.

Elgersma Y, Sweatt JD, Giese KP (2004) Mouse genetic approaches to investigating calcium/calmodulin-dependent protein kinase II function in plasticity and cognition. J Neurosci 24:8410–8415PubMedCrossRef

28.

Engelender S (2008) Ubiquitination of alpha-synuclein and autophagy in Parkinson’s disease. Autophagy 4:372–374PubMed

29.

Feng Z, Jin S, Zupnick A et al (2006) p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 25:1–7PubMedCrossRef

30.

Finkbeiner S, Mitra S (2008) The ubiquitin–proteasome pathway in Huntington’s disease. Sci World J 8:421–433

31.

Fleisher AS, Raman R, Siemers ER et al (2008) Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65:1031–1038PubMedCrossRef

32.

Fortun J, Li J, Go J, Fenstermaker A, Fletcher BS, Notterpek L (2005) Impaired proteasome activity and accumulation of ubiquitinated substrates in a hereditary neuropathy model. J Neurochem 92:1531–1541PubMedCrossRef

33.

Fujiwara M, Marusawa H, Wang HQ et al (2008) Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene 27:6002–6011PubMedCrossRef

34.

Gaig C, Marti MJ, Ezquerra M, Rey MJ, Cardozo A, Tolosa E (2007) G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies. J Neurol Neurosurg Psychiatry 78:626–628PubMedCrossRef

35.

Gibson SE, Zeng WF, Weil RJ, Prayson RA (2008) Aurora B kinase expression in ependymal neoplasms. Appl Immunohistochem Mol Morphol 16:274–278PubMedCrossRef

36.

Glessner JT, Wang K, Cai G (2009) Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 459:569–573PubMedCrossRef

37.

Golden JA, Bracilovic A, McFadden KA, Beesley JS, Rubenstein JL, Grinspan JB (1999) Ectopic bone morphogenetic proteins 5 and 4 in the chicken forebrain lead to cyclopia and holoprosencephaly. Proc Natl Acad Sci USA 96:2439–2444PubMedCrossRef

38.

Gong B, Leznik E (2007) The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect 20:365–370PubMedCrossRef

39.

Grant EP, Michalek MT, Goldberg AL, Rock KL (1995) Rate of antigen degradation by the ubiquitin–proteasome pathway influences MHC class I presentation. J Immunol 155:3750–3758PubMed

40.

Guardavaccaro D, Kudo Y, Boulaire J et al (2003) Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell 4:799–812PubMedCrossRef

41.

Haas AL, Warms JV, Hershko A, Rose IA (1982) Ubiquitin-activating enzyme mechanism and role in protein–ubiquitin conjugation. J Biol Chem 257:2543–2548PubMed

42.

Hanai J, Cao P, Tanksale P et al (2007) The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 117:3940–3951PubMed

43.

Hart M, Concordet JP, Lassot I et al (1999) The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 9:207–210PubMedCrossRef

44.

Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425–479PubMedCrossRef

45.

Hesson L, Bièche I, Krex D et al (2004) Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 23:2408–2419PubMedCrossRef

46.

Holm IE, Englund E, Mackenzie IR, Johannsen P, Isaacs AM (2007) A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. J Neuropathol Exp Neurol 66:884–891PubMedCrossRef

47.

Hong S, Kim SJ, Ka S, Choi I, Kang S (2002) USP7, a ubiquitin-specific protease, interacts with ataxin-1, the SCA1 gene product. Mol Cell Neurosci 20:298–306PubMedCrossRef

48.

Hsu JY, Reimann JD, Sorensen CS, Lukas J, Jackson PK (2002) E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC (Cdh1). Nat Cell Biol 4:358–366PubMedCrossRef

49.

Huang Y, Song YJ, Murphy K et al (2008) LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. Acta Neuropathol 116:639–646PubMedCrossRef

50.

Huynh DP, Nguyen DT, Pulst-Korenberg JB, Brice A, Pulst SM (2007) Parkin is an E3 ubiquitin-ligase for normal and mutant ataxin-2 and prevents ataxin-2-induced cell death. Exp Neurol 203:531–541PubMedCrossRef

51.

Iwata A, Nagashima Y, Matsumoto L et al (2009) Intranuclear degradation of polyglutamine aggregates by the ubiquitin–proteasome system. J Biol Chem 284:9796–9803PubMedCrossRef

52.

Jones RJ, Chen Q, Voorhees PM et al (2008) Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage-independent p53 phosphorylation in mantle cell lymphoma. Clin Cancer Res 14:5416–5425PubMedCrossRef

53.

Josephs KA, Lin WL, Ahmed Z, Stroh DA, Graff-Radford NR, Dickson DW (2008) Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions. Acta Neuropathol 116:159–167PubMedCrossRef

54.

Kaelin WG (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673–682PubMedCrossRef

55.

Kang Y, Vossler RA, Diaz-Martinez LA, Winter NS, Clarke DJ, Walters KJ (2006) UBL/UBA ubiquitin receptor proteins bind a common tetraubiquitin chain. J Mol Biol 356:1027–1035PubMedCrossRef

56.

Kannanayakal TJ, Mendell JR, Kuret J (2008) Casein kinase 1 alpha associates with the tau-bearing lesions of inclusion body myositis. Neurosci Lett 431:141–145PubMedCrossRef

57.

Kawashima T, Furuta A, Doh-ura K, Kikuchi H, Iwaki T (2000) Ubiquitin-immunoreactive skein-like inclusions in the neostriatum are not restricted to amyotrophic lateral sclerosis, but are rather aging-related structures. Acta Neuropathol 100:43–49PubMedCrossRef

58.

Kim BY, Olzmann JA, Barsh GS, Chin LS, Li L (2007) Spongiform neurodegeneration-associated E3 ligase Mahogunin ubiquitylates TSG101 and regulates endosomal trafficking. Mol Biol Cell 18:1129–1142PubMedCrossRef

59.

Kim MJ, Chia IV, Costantini F (2008) SUMOylation target sites at the C terminus protect Axin from ubiquitination and confer protein stability. FASEB J 22:3785–3794PubMedCrossRef

60.

Kim SH, Shi Y, Hanson KA et al (2009) Potentiation of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasome-targeting factor, ubiquilin 1. J Biol Chem 284:8083–8092PubMedCrossRef

61.

Kinoshita A, Whelan CM, Berezovska O, Hyman BT (2002) The gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells. J Biol Chem 277:28530–28536PubMedCrossRef

62.

Kirkin V, McEwan DG, Novak I, Dikic I (2009) A role for ubiquitin in selective autophagy. Mol Cell 34:259–269PubMedCrossRef

63.

Ko HS, Bailey R, Smith WW et al (2009) CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci USA 106:2897–2902PubMedCrossRef

64.

Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S (1999) A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96:635–644PubMedCrossRef

65.

Koepp DM, Schaefer LK, Ye X et al (2001) Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294:173–177PubMedCrossRef

66.

Konishi Y, Stegmüller J, Matsuda T, Bonni S, Bonni A (2004) Cdh1-APC controls axonal growth and patterning in the mammalian brain. Science 303:1026–1030PubMedCrossRef

67.

Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10:524–530PubMedCrossRef

68.

Kristiansen M, Deriziotis P, Dimcheff DE et al (2007) Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell 26:175–188PubMedCrossRef

69.

Kristiansen M, Messenger MJ, Klohn PC et al (2005) Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis. J Biol Chem 280:38851–38861PubMedCrossRef

70.

Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137:609–622PubMedCrossRef

71.

Kruse JP, Gu W (2009) MSL2 promotes Mdm2-independent cytoplasmic localization of p53. J Biol Chem 284:3250–3263PubMedCrossRef

72.

Lagirand-Cantaloube J, Cornille K, Csibi A, Batonnet-Pichon S, Leibovitch MP, Leibovitch SA (2009) Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo. PLoS ONE 4:e4973PubMedCrossRef

73.

Lathia JD, Mattson MP, Cheng A (2008) Notch: from neural development to neurological disorders. J Neurochem 107:1471–1481PubMedCrossRef

74.

Lebre AS, Jamot L, Takahashi J et al (2001) Ataxin-7 interacts with a Cbl-associated protein that it recruits into neuronal intranuclear inclusions. Hum Mol Genet 10:1201–1213PubMedCrossRef

75.

Lee JT, Wheeler TC, Li L, Chin LS (2008) Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. Hum Mol Genet 17:906–917PubMedCrossRef

76.

Lehman NL, Danenberg PV (2000) Modulation of RTX cytotoxicity by thymidine and dipyridamole in vitro: implications for chemotherapy. Cancer Chemother Pharmacol 45:142–148PubMedCrossRef

77.

Lehman NL, Tibshirani R, Hsu JY et al (2007) Oncogenic regulators and substrates of the anaphase promoting complex/cyclosome are frequently overexpressed in malignant tumors. Am J Pathol 170:1793–1805PubMedCrossRef

78.

Lehman NL, van de Rijn M, Jackson PK (2005) Screening of tissue microarrays for ubiquitin proteasome system components in tumors. Methods Enzymol 399:334–355PubMedCrossRef

79.

Lehman NL, Verschuren EW, Hsu JY, Cherry AM, Jackson PK (2006) Overexpression of the anaphase promoting complex/cyclosome inhibitor Emi1 leads to tetraploidy and genomic instability of p53-deficient cells. Cell Cycle 5:1569–1573PubMed

80.

Liani E, Eyal A, Avraham E et al (2004) Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson’s disease. Proc Natl Acad Sci USA 101:5500–5505PubMedCrossRef

81.

Liscic RM, Grinberg LT, Zidar J, Gitcho MA, Cairns NJ (2008) ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol 15:772–780PubMedCrossRef

82.

Liu S, Bromley-Brits K, Xia K, Mittelholtz J, Wang R, Song W (2008) TMP21 degradation is mediated by the ubiquitin–proteasome pathway. Eur J Neurosci 28:1980–1988PubMedCrossRef

83.

Liu YC (2004) Ubiquitin ligases and the immune response. Annu Rev Immunol 22:81–127PubMedCrossRef

84.

Lloyd SE, Maytham EG, Pota H et al (2009) HECTD2 is associated with susceptibility to mouse and human prion disease. PLoS Genet 5:e1000383PubMedCrossRef

85.

Lu X, Liu S, Kornberg TB (2006) The C-terminal tail of the Hedgehog receptor Patched regulates both localization and turnover. Genes Dev 20:2539–2551PubMedCrossRef

86.

Lusher ME, Lindsey JC, Latif F, Pearson AD, Ellison DW, Clifford SC (2002) Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer Res 62:5906–5911PubMed

87.

Mackenzie IR, Bigio EH, Ince PG et al (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61:427–434PubMedCrossRef

88.

Makedonski K, Abuhatzira L, Kaufman Y, Razin A, Shemer R (2005) MeCP2 deficiency in Rett syndrome causes epigenetic aberrations at the PWS/AS imprinting center that affects UBE3A expression. Hum Mol Genet 14:1049–1058PubMedCrossRef

89.

Manfredi MG, Ecsedy JA, Meetze KA et al (2007) Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 104:4106–4111PubMedCrossRef

90.

Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB (2002) PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277:5484–5489PubMedCrossRef

91.

Miklossy J, Steele JC, Yu S et al (2008) Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). Acta Neuropathol 116:625–637PubMedCrossRef

92.

Michalowski MB, de Fraipont F, Michelland S et al (2006) Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet 166:74–81PubMedCrossRef

93.

Miller JJ, Summers MK, Hansen DV et al (2006) Emi1 stably binds and inhibits the anaphase-promoting complex/cyclosome as a pseudosubstrate inhibitor. Genes Dev 20:2410–2420PubMedCrossRef

94.

Mishra A, Dikshit P, Purkayastha S, Sharma J, Nukina N, Jana NR (2008) E6-AP promotes misfolded polyglutamine proteins for proteasomal degradation and suppresses polyglutamine protein aggregation and toxicity. J Biol Chem 283:7648–7656PubMedCrossRef

95.

Morishima Y, Wang AM, Yu Z, Pratt WB, Osawa Y, Lieberman AP (2008) CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins. Hum Mol Genet 17:3942–3952PubMedCrossRef

96.

Morreale G, Conforti L, Coadwell J, Wilbrey AL, Coleman MP (2009) Evolutionary divergence of valosin-containing protein/cell division cycle protein 48 binding interactions among endoplasmic reticulum-associated degradation proteins. FEBS J 276:1208–1220PubMedCrossRef

97.

Mosesson Y, Shtiegman K, Katz M et al (2003) Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem 278:21323–21326PubMedCrossRef

98.

Muller S, Matunis MJ, Dejean A (1998) Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 17:61–70PubMedCrossRef

99.

Murakami G, Watabe T, Takaoka K, Miyazono K, Imamura T (2003) Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol Biol Cell 14:2809–2817PubMedCrossRef

100.

Neben K, Korshunov A, Benner A et al (2004) Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 64:3103–3111PubMedCrossRef

101.

Neumann M, Mackenzie IR, Cairns NJ et al (2007) TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol 66:152–157PubMedCrossRef

102.

Nonis D, Schmidt MH, van de Loo S et al (2008) Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking. Cell Signal 20:1725–1739PubMedCrossRef

103.

Parkinson N, Ince PG, Smith MO et al (2006) ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 67:1074–1077PubMedCrossRef

104.

Ramesh Babu J, Lamar Seibenhener M, Peng J et al (2008) Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. J Neurochem 106:107–120PubMedCrossRef

105.

Reimann JD, Freed E, Hsu JY, Kramer ER, Peters JM, Jackson PK (2001) Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex. Cell 105:645–655PubMedCrossRef

106.

Richardson PG, Sonneveld P, Schuster M et al (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110:3557–3560PubMedCrossRef

107.

Riley BE, Xu Y, Zoghbi HY, Orr HT (2004) The effects of the polyglutamine repeat protein ataxin-1 on the UbL-UBA protein A1Up. J Biol Chem 279:42290–42301PubMedCrossRef

108.

Roeber S, Mackenzie IR, Kretzschmar HA, Neumann M (2008) TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol 116:147–157PubMedCrossRef

109.

Rott R, Szargel R, Haskin J et al (2008) Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J Biol Chem 283:3316–3328PubMedCrossRef

110.

Sadeh R, Breitschopf K, Bercovich B et al (2008) The N-terminal domain of MyoD is necessary and sufficient for its nuclear localization-dependent degradation by the ubiquitin system. Proc Natl Acad Sci USA 105:15690–15695PubMedCrossRef

111.

Sartori S, Anesi L, Polli R et al (2008) Angelman syndrome due to a novel splicing mutation of the UBE3A gene. J Child Neurol 23:912–915PubMedCrossRef

112.

Schimmel J, Larsen KM, Matic I et al (2008) The ubiquitin–proteasome system is a key component of the SUMO-2/3 cycle. Mol Cell Proteomics 7:2107–2122PubMedCrossRef

113.

Schwartz AL, Ciechanover A (2009) Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 49:73–96PubMedCrossRef

114.

Sekine S, Shibata T, Kokubu A et al (2002) Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol 161:1997–2001PubMed

115.

Setsuie R, Wada K (2007) The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int 51:105–111PubMedCrossRef

116.

Sheng Y, Laister RC, Lemak A et al (2008) Molecular basis of Pirh2-mediated p53 ubiquitylation. Nat Struct Mol Biol 15:1334–1342PubMedCrossRef

117.

Shiba K, Arai T, Sato S et al (2009) Parkin stabilizes PINK1 through direct interaction. Biochem Biophys Res Commun 383:331–335PubMedCrossRef

118.

Song C, Wang Q, Li CC (2007) Characterization of the aggregation-prevention activity of p97/valosin-containing protein. Biochemistry 46:14889–14898PubMedCrossRef

119.

Song SJ, Song MS, Kim SJ et al (2009) Aurora A regulates prometaphase progression by inhibiting the ability of RASSF1A to suppress APC-Cdc20 activity. Cancer Res 69:2314–2323PubMedCrossRef

120.

Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, Abeliovich A (2003) Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37:735–749PubMedCrossRef

121.

Ström AL, Forsgren L, Holmberg M (2005) A role for both wild-type and expanded ataxin-7 in transcriptional regulation. Neurobiol Dis 20:646–655PubMedCrossRef

122.

Tai HC, Schuman EM (2008) Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci 9:826–838PubMedCrossRef

123.

Tan JM, Wong ES, Dawson VL, Dawson TM, Lim KL (2007) Lysine 63-linked polyubiquitin potentially partners with p62 to promote the clearance of protein inclusions by autophagy. Autophagy 4(2) (in press)

124.

Tank EM, True HL (2009) Disease-associated mutant ubiquitin causes proteasomal impairment and enhances the toxicity of protein aggregates. PLoS Genet 5:e1000382PubMedCrossRef

125.

Todi SV, Winborn BJ, Scaglione KM, Blount JR, Travis SM, Paulson HL (2009) Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3. EMBO J 28:372–382PubMedCrossRef

126.

Tortosa E, Santa-Maria I, Moreno F, Lim F, Perez M, Avila J (2009) Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein. J Alzheimers Dis (in press)

127.

Tydlacka S, Wang CE, Wang X, Li S, Li XJ (2008) Differential activities of the ubiquitin–proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J Neurosci 28:13285–13295PubMedCrossRef

128.

VanderPorten EC, Taverna P, Hogan JN, Ballinger MD, Flanagan WM, Fucini RV (2009) The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther 8:930–939PubMedCrossRef

129.

Varghese B, Barriere H, Carbone CJ et al (2008) Polyubiquitination of prolactin receptor stimulates its internalization, postinternalization sorting, and degradation via the lysosomal pathway. Mol Cell Biol 28:5275–5287PubMedCrossRef

130.

Verschuren EW, Ban KH, Masek MA, Lehman NL, Jackson PK (2007) Loss of Emi1-dependent anaphase-promoting complex/cyclosome inhibition deregulates E2F target expression and elicits DNA damage-induced senescence. Mol Cell Biol 27:7955–7965PubMedCrossRef

131.

Vissers JH, Nicassio F, van Lohuizen M, Di Fiore PP, Citterio E (2008) The many faces of ubiquitinated histone H2A: insights from the DUBs. Cell Div 3:8PubMedCrossRef

132.

Wang HL, He CY, Chou AH, Yeh TH, Chen YL, Li AH (2007) Polyglutamine-expanded ataxin-7 decreases nuclear translocation of NF-kappaB p65 and impairs NF-kappaB activity by inhibiting proteasome activity of cerebellar neurons. Cell Signal 19:573–581PubMedCrossRef

133.

Wang J, Wang CE, Orr A, Tydlacka S, Li SH, Li XJ (2008) Impaired ubiquitin–proteasome system activity in the synapses of Huntington’s disease mice. J Cell Biol 180:1177–1189PubMedCrossRef

134.

Weihl CC, Temiz P, Miller SE et al (2008) TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 79:1186–1189PubMedCrossRef

135.

Westwood FR, Scott RC, Marsden AM, Bigley A, Randall K (2008) Rosuvastatin: characterization of induced myopathy in the rat. Toxicol Pathol 36:345–352PubMedCrossRef

136.

Williams A, Jahreiss L, Sarkar S et al (2006) Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr Top Dev Biol 76:89–101PubMedCrossRef

137.

Wojcik C, Rowicka M, Kudlicki A et al (2006) Valosin-containing protein (p97) is a regulator of endoplasmic reticulum stress and of the degradation of N-end rule and ubiquitin–fusion degradation pathway substrates in mammalian cells. Mol Biol Cell 17:4606–4618PubMedCrossRef

138.

Wojcik C, Yano M, DeMartino GN (2004) RNA interference of valosin-containing protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/proteasome-dependent proteolysis. J Cell Sci 117:281–292PubMedCrossRef

139.

Wong GT, Manfra D, Poulet FM et al (2004) Chronic treatment with the gamma-secretase inhibitor LY-411, 575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279:12876–12882PubMedCrossRef

140.

Wong HK, Bauer PO, Kurosawa M et al (2008) Blocking acid-sensing ion channel 1 alleviates Huntington’s disease pathology via an ubiquitin–proteasome system-dependent mechanism. Hum Mol Genet 17:3223–3235PubMedCrossRef

141.

Xia Y, Padre RC, De Mendoza TH, Bottero V, Tergaonkar VB, Verma IM (2009) Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc Natl Acad Sci USA 106:2629–2634PubMedCrossRef

142.

Xiong H, Wang D, Chen L et al (2009) Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 119:650–660PubMedCrossRef

143.

Yamanaka K, Vande Velde C, Eymard-Pierre E, Bertini E, Boespflug-Tanguy O, Cleveland DW (2003) Unstable mutants in the peripheral endosomal membrane component ALS2 cause early-onset motor neuron disease. Proc Natl Acad Sci USA 100:16041–16046PubMedCrossRef

144.

Yang B, Hahn YS, Hahn CS, Braciale TJ (1996) The requirement for proteasome activity class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen. J Exp Med 183:1545–1552PubMedCrossRef

145.

Yang Y, Allen E, Ding J, Wang W (2007) Giant axonal neuropathy. Cell Mol Life Sci 64:601–609PubMedCrossRef

146.

Yashiro K, Riday TT, Condon KH et al (2009) Ube3a is required for experience-dependent maturation of the neocortex. Nat Neurosci (in press)

147.

Yi JJ, Ehlers MD (2005) Ubiquitin and protein turnover in synapse function. Neuron 47:629–632PubMedCrossRef

148.

Zhai Q, Wang J, Kim A et al (2003) Involvement of the ubiquitin–proteasome system in the early stages of wallerian degeneration. Neuron 39:217–225PubMedCrossRef

149.

Zimprich A, Biskup S, Leitner P et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607PubMedCrossRef

Title: The ubiquitin proteasome system in neuropathology
Author: Norman L. Lehman
Publication date: 01-09-2009
Publisher: Springer-Verlag
Published in: Acta Neuropathologica / Issue 3/2009
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-009-0560-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The ubiquitin proteasome system in neuropathology

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing

p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis

Nitrosative stress and inducible nitric oxide synthase expression in periventricular leukomalacia

Announcing the winner of the 2009 Kurt Jellinger Prize

54. Annual Meeting of the German Society of Neuropathology and Neuroanatomy (DGNN)

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma